• Important Safety Information  |  
• Site Map  |  
• CRESTOR Consumer Site

• E-mail page
• Print page
• Text size:   

CRESTOR^® (rosuvastatin calcium) is a single-agent solution that may help your at-risk patients reach goal without titration, while also helping to slow the progression of atherosclerosis.^1,14,15

Start with a single-agent solution

• CRESTOR is priced the same at every dose (AWP)²⁹
• No restrictions on time of day for administration — can be taken with or without food¹

*Therapy should be individualized according to goal of therapy and response. After initiation and/or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.¹

^†Patients taking cyclosporine, Asian patients, and patients with severe renal insufficiency.¹

Significant LDL-C reductions at each dose^1,30

^‡P<.001 vs 7% placebo.^1,30

• Combination therapy with gemfibrozil should be avoided. If CRESTOR is used in combination with gemfibrozil, the dose of CRESTOR should be limited to 10 mg once daily; in patients taking cyclosporine, therapy should be limited to CRESTOR 5 mg once daily¹
• In patients taking a combination of lopinavir and ritonavir, the dose of CRESTOR should be limited to 10 mg once daily¹

CRESTOR helps get your at-risk patients to goal^§11,12,13

^§According to the third report of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) update, the LDL-C goal is <160 mg/dL for lower-risk patients, <130 mg/dL for moderate-risk patients, <130 mg/dL (optional goal of <100 mg/dL) for moderately at-risk patients, <100 mg/dL for at-risk patients, and an optional goal of <70 mg/dL for very at-risk patients.^14,15

^‖In 3 titration trials of patients with type 2 diabetes treated with a starting dose of CRESTOR 10 mg.

In the ANDROMEDA trial (n=240), 94% reached LDL-C goal of <96.5 mg/dL at 8 weeks. There was a mean LDL-C reduction of 51% from baseline of 131 mg/dL. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.¹¹

In the CORALL trial (n=130), 82% reached LDL-C goal of <100 mg/dL at 6 weeks. There was a mean LDL-C reduction of 46% from baseline of 163 mg/dL. The primary end point, the percentage change from baseline in ApoB/ApoA1 ratio after 6 weeks, was not significantly different between CRESTOR and atorvastatin. LDL-C goal achievement was another end point.¹²

In the URANUS trial (n=232), 65% reached LDL-C goal of <100 mg/dL at 4 weeks. There was a mean LDL-C reduction of 48% from baseline of 178 mg/dL. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.¹³

Read about pharmacokinetics in at-risk patients who are taking CRESTOR.